About the Authors

Jennifer Riley

Affiliation Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, United Kingdom

Stephen Brand

Affiliation Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, United Kingdom

Michael Voice

Affiliation CYPEX, Dundee, United Kingdom

Ivan Caballero

Affiliation Molecular Discovery Research-Tres Cantos, GlaxoSmithKline, Centro de Investigación Básica, Tres Cantos, Spain

David Calvo

Affiliation Molecular Discovery Research-Tres Cantos, GlaxoSmithKline, Centro de Investigación Básica, Tres Cantos, Spain

Kevin D. Read

k.read@dundee.ac.uk

Affiliation Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, United Kingdom

Competing Interests

DC and IC are employed by GlaxoSmithKline. This does not alter their adherence to all PLOS NTDs policies on sharing data and materials. They have declared that no competing interests exist. MV is director of CYPEX Ltd. This does not alter his adherence to all PLOS NTDs policies on sharing data and materials. However, he cannot make the plasmid (or E.coli containing the plasmid) freely available as the ompA part is patented and would be in breach of his licence. He has no competing interests although it should be noted that the T. cruzi CYP51 enzyme developed in this paper will be made available for sale commercially through CYPEX. KR, JR and SB have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: KDR IC DC JR. Performed the experiments: JR IC DC. Analyzed the data: JR IC DC SB. Contributed reagents/materials/analysis tools: MV. Wrote the paper: JR SB MV IC DC KDR.